The Boydsense diabetes device has been chosen among the outstanding innovations of the 2019 Redefing Early Stage Investments (Resi) innovation challenge.It is a non -invasive technology for the analysis of the breath of this company recognized for its innovation and potential to revolutionize the glucose monitoring industry.
The Boydsense platform will allow consumers and health care services providers to use breath as an non -invasive means to detect and monitor diseases such as cancer, obesity and asthma, among others.
The Breath meter G-Sense, the company's first product, is a portable device that allows people with diabetes to accurately measure blood glucose values through COV present in breath without cost,The pain and social stigma linked to conventional glucose meters with digital puncture.
Boydsense is a medical technology company that develops affordable and non -invasive tools to measure critical biomarkers present in the exhaled breath.Its mission is to build a platform that makes possible the capture and visualization of biofirms, at any time and anywhere, to help consumers better manage their diseases.
"Being one of the outstanding finalists in this prestigious event of the sector confirms what our leadership team and current investors already know, that Boydsense technology is prepared to play a central role in the transition to non -invasive diabetes monitoring systemsand other chronic diseases, "said Bruno Thuillier, CEO of Boydsense.
The 2019 Resi 2019 innovation challenge is open to international companies in the initial phase within the fields of biotechnology, medical, diagnostic and digital health technology.Of the 130 initial candidates, the Life Science Nation scientific review committee personally selected 38 finalists to present their technologies during the conference and the winners were chosen from the vote of the attendees.
"Both the second prize of the Resi innovation challenge, and the enthusiasm we receive from investors and colleagues have been a great impulse for Boydsense to continue working with a view to launch our first commercial product and make it available to thePeople with diabetes, "Thuillier said.